Literature DB >> 2464703

Amino acid sequence of a conserved neutralizing epitope of murine coronaviruses.

W Luytjes1, D Geerts, W Posthumus, R Meloen, W Spaan.   

Abstract

We identified the binding site of monoclonal antibody 19.2, which cross-neutralizes several mouse hepatitis virus (MHV) strains, inhibits fusion of MHV-infected cells, and protects against lethal infection (P. J. Talbot and M. J. Buchmeier, Virus Res. 2:317-328, 1985). We used fusion proteins, generated by expression of fragments of the MHV A59 E2 gene in pEX plasmids, and synthetic peptides in a PEPSCAN.

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2464703      PMCID： PMC247841     

Source DB:  PubMed          Journal:  J Virol        ISSN： 0022-538X            Impact factor:   5.103


  22 in total

1.  Characterization of the structural proteins of the murine coronavirus strain A59 using monoclonal antibodies.

Authors:  W Gilmore; J O Fleming; S A Stohlman; L P Weiner
Journal:  Proc Soc Exp Biol Med       Date:  1987-06

2.  Small peptides induce antibodies with a sequence and structural requirement for binding antigen comparable to antibodies raised against the native protein.

Authors:  H M Geysen; S J Barteling; R H Meloen
Journal:  Proc Natl Acad Sci U S A       Date:  1985-01       Impact factor: 11.205

3.  Epitope-specific antibody response to murine hepatitis virus-4 (strain JHM).

Authors:  P J Talbot; A A Salmi; R L Knobler; M J Buchmeier
Journal:  J Immunol       Date:  1985-02       Impact factor: 5.422

4.  The peplomer protein E2 of coronavirus JHM as a determinant of neurovirulence: definition of critical epitopes by variant analysis.

Authors:  H Wege; J Winter; R Meyermann
Journal:  J Gen Virol       Date:  1988-01       Impact factor: 3.891

5.  Pathogenicity of antigenic variants of murine coronavirus JHM selected with monoclonal antibodies.

Authors:  J O Fleming; M D Trousdale; F A el-Zaatari; S A Stohlman; L P Weiner
Journal:  J Virol       Date:  1986-06       Impact factor: 5.103

6.  Virulence of La Crosse virus is under polygenic control.

Authors:  R S Janssen; N Nathanson; M J Endres; F Gonzalez-Scarano
Journal:  J Virol       Date:  1986-07       Impact factor: 5.103

7.  Protective effect of monoclonal antibodies on lethal mouse hepatitis virus infection in mice.

Authors:  K Nakanaga; K Yamanouchi; K Fujiwara
Journal:  J Virol       Date:  1986-07       Impact factor: 5.103

8.  Proteolytic cleavage of the E2 glycoprotein of murine coronavirus: activation of cell-fusing activity of virions by trypsin and separation of two different 90K cleavage fragments.

Authors:  L S Sturman; C S Ricard; K V Holmes
Journal:  J Virol       Date:  1985-12       Impact factor: 5.103

9.  Primary structure of the glycoprotein E2 of coronavirus MHV-A59 and identification of the trypsin cleavage site.

Authors:  W Luytjes; L S Sturman; P J Bredenbeek; J Charite; B A van der Zeijst; M C Horzinek; W J Spaan
Journal:  Virology       Date:  1987-12       Impact factor: 3.616

10.  Evidence for a coiled-coil structure in the spike proteins of coronaviruses.

Authors:  R J de Groot; W Luytjes; M C Horzinek; B A van der Zeijst; W J Spaan; J A Lenstra
Journal:  J Mol Biol       Date:  1987-08-20       Impact factor: 5.469
View more
  29 in total

1.  Comparison of the nucleotide and deduced amino acid sequences of the S genes specified by virulent and avirulent strains of bovine coronaviruses.

Authors:  X M Zhang; K G Kousoulas; J Storz
Journal:  Virology       Date:  1991-07       Impact factor: 3.616

2.  Neutralization-resistant variants of a neurotropic coronavirus are generated by deletions within the amino-terminal half of the spike glycoprotein.

Authors:  T M Gallagher; S E Parker; M J Buchmeier
Journal:  J Virol       Date:  1990-02       Impact factor: 5.103

3.  The S2 subunit of the spike glycoprotein of bovine coronavirus mediates membrane fusion in insect cells.

Authors:  D W Yoo; M D Parker; L A Babiuk
Journal:  Virology       Date:  1991-01       Impact factor: 3.616

4.  Analysis of murine coronavirus surface glycoprotein functions by using monoclonal antibodies.

Authors:  E Routledge; R Stauber; M Pfleiderer; S G Siddell
Journal:  J Virol       Date:  1991-01       Impact factor: 5.103

5.  Identification of an immunodominant linear neutralization domain on the S2 portion of the murine coronavirus spike glycoprotein and evidence that it forms part of complex tridimensional structure.

Authors:  C Daniel; R Anderson; M J Buchmeier; J O Fleming; W J Spaan; H Wege; P J Talbot
Journal:  J Virol       Date:  1993-03       Impact factor: 5.103

6.  Receptor-induced conformational changes of murine coronavirus spike protein.

Authors:  Shutoku Matsuyama; Fumihiro Taguchi
Journal:  J Virol       Date:  2002-12       Impact factor: 5.103

7.  A single amino acid change within antigenic domain II of the spike protein of bovine coronavirus confers resistance to virus neutralization.

Authors:  D Yoo; D Deregt
Journal:  Clin Diagn Lab Immunol       Date:  2001-03

8.  Protective immunity against murine hepatitis virus (MHV) induced by intranasal or subcutaneous administration of hybrids of tobacco mosaic virus that carries an MHV epitope.

Authors:  M Koo; M Bendahmane; G A Lettieri; A D Paoletti; T E Lane; J H Fitchen; M J Buchmeier; R N Beachy
Journal:  Proc Natl Acad Sci U S A       Date:  1999-07-06       Impact factor: 11.205

9.  Newcastle disease virus (NDV) marker vaccine: an immunodominant epitope on the nucleoprotein gene of NDV can be deleted or replaced by a foreign epitope.

Authors:  Teshome Mebatsion; Marck J M Koolen; Leonie T C de Vaan; Niels de Haas; Marian Braber; Angela Römer-Oberdörfer; Paul van den Elzen; Pieter van der Marel
Journal:  J Virol       Date:  2002-10       Impact factor: 5.103

10.  Identification of an antigenic determinant on the S2 domain of the severe acute respiratory syndrome coronavirus spike glycoprotein capable of inducing neutralizing antibodies.

Authors:  Hong Zhang; Guangwen Wang; Jian Li; Yuchun Nie; Xuanling Shi; Gewei Lian; Wei Wang; Xiaolei Yin; Yang Zhao; Xiuxia Qu; Mingxiao Ding; Hongkui Deng
Journal:  J Virol       Date:  2004-07       Impact factor: 5.103
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.